Release Details

SOUTH PLAINFIELD, N.J., May 11, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards program aimed at providing funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates. The program, in its inaugural year, will focus on Duchenne muscular dystrophy (DMD).

"From the time PTC was founded, patient organizations have been valuable partners to us and have played important roles in our research and development programs. We are excited to support these groups and enable them to use their creativity and experience to raise awareness and make a difference for the DMD community," stated Stuart Peltz, Ph.D., CEO of PTC Therapeutics, Inc. 

The program is aimed at improving the diagnosis and treatment of DMD patients, increasing the visibility of this devastating rare disorder, and educating the general public and healthcare professionals, as well as identifying and fostering the next generation of DMD patient advocates. Five one-year awards of up to $30,000 each will be given to the most creative, feasible and sustainable proposals identified by a panel of judges. The deadline for submission of proposals is June 22, 2015 and awards will be announced on World Duchenne Awareness Day, on September 7th.

Mary Frances Harmon, who recently joined PTC and will be Global Head of Patient Advocacy, noted "I'm proud to be part of the PTC team. The STRIVE awards program underscores our commitment to advocacy in the rare disease community and demonstrates the importance of increasing awareness and education about rare diseases around the world. I look forward to seeing the great ideas coming forward and working with the organizations to advance the initiatives selected."

For more information, please visit the STRIVE Awards Program's website at: www.ptcbio.com/strive

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com.

For More Information:
Investors:
Emily Hill
+1(908) 912-9327
ehill@ptcbio.com

Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com

Patient Organizations:
Mary Frances Harmon
+1 (908) 912-9205 or (866) 282-5873
mharmon@ptcbio.com

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact, contained in this release, including statements regarding the future expectations, plans and prospects for PTC, are forward-looking statements. Other forward-looking statements may be identified by the words "plan," "guidance," "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this release except as required by law.

Logo - http://photos.prnewswire.com/prnh/20010919/PTCLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ptc-therapeutics-launches-strive-grant-award-program-300080747.html

SOURCE PTC Therapeutics, Inc.